Tomasik Kotin Kasserman currently represents patients in the Chicagoland area who have ingested Januvia and other type 2 diabetes drugs. Hundreds of cases have been filed nationwide by patients who have ingested Januvia and been diagnosed with pancreatitis and pancreatic cancer.
Millions of Americans suffer from type 2 diabetes, a condition characterized by low insulin production. Januvia is a prescription drug meant to help adult patients with type 2 diabetes regulate insulin levels.
In March 2013, the FDA announced that it was evaluating unpublished findings by academic researchers that suggested an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.
While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. Pancreatitis can be a precursor to pancreatic cancer. According to the American Cancer Society, for all states of pancreatic cancer combined, the one-year relative survival rate is 20%, and the five-year rate is 4%.
Adults with type 2 diabetes taking the drugs Januvia, Janumet, Byetta, Victoza or Bydureon have an increased risk of developing pancreatitis and pancreatic cancer.
A study done by the Islet Research Center at the University of California, Los Angeles, found a six-fold increase of reported cases of pancreatitis linked to patients taking Januvia or Byetta; a 2.9-fold increase in reported cases of pancreatic cancer among those taking Byetta; and a 2.7-fold increase of reported pancreatic cancer among Januvia users.
If you have been diagnosed with pancreatic cancer or a pancreatic condition while taking one of these drugs, talk to a lawyer at Tomasik Kotin Kasserman – at no cost – today. You are entitled to explore your legal rights, which may include compensation for medical bills, lost earnings, and pain and suffering.